Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Inventory (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Inventory for 14 consecutive years, with $12.9 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 3.67% to $12.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.9 million through Dec 2025, up 3.67% year-over-year, with the annual reading at $12.9 million for FY2025, 3.67% up from the prior year.
  • Inventory hit $12.9 million in Q4 2025 for Corcept Therapeutics, up from $12.3 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $14.4 million in Q1 2025 to a low of $4.7 million in Q2 2021.
  • Historically, Inventory has averaged $7.9 million across 5 years, with a median of $7.1 million in 2023.
  • Biggest five-year swings in Inventory: dropped 5.24% in 2021 and later skyrocketed 99.83% in 2025.
  • Year by year, Inventory stood at $5.0 million in 2021, then grew by 22.29% to $6.1 million in 2022, then rose by 26.72% to $7.7 million in 2023, then surged by 60.57% to $12.4 million in 2024, then rose by 3.67% to $12.9 million in 2025.
  • Business Quant data shows Inventory for CORT at $12.9 million in Q4 2025, $12.3 million in Q3 2025, and $12.3 million in Q2 2025.